Melanie Senior
Contributor
Experienced biopharmaceutical industry analyst, reporter & commentator following strategic, commercial and scientific issues affecting the sector. Regular contributor to Nature Biotechnology, Informa Business Intelligence (IN VIVO, Datamonitor, Scrip) and EY Life Sciences. Specialist & feature coverage and consulting across market access, pricing, outcomes-based care, precision medicine, digital health, AI, R&D strategies and consumer empowerment for a range of clients in biopharma and investment community.
Latest From Melanie Senior
Why US Payers Aren’t Reimbursing Obesity Meds
Payers are restricting access to obesity drugs due to huge patient numbers and a wave of innovation in other areas
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?
Deals In 2023: Partnerships And Modest M&A
Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.
On The Cusp: UK Biotech Verona Pharma Awaits Potential Blockbuster
Verona Pharma’s Phase III ensifentrine, if approved, would be the first new dual-mechanism treatment class for COPD patients in decades. It could propel the UK-based biotech toward profitability, or into the arms of a larger partner.